Marketing status and analysis of Fostamatinib

Fostamatinib (Fostamatinib) was approved in the United States in April 2018 for the treatment of chronic immune thrombocytopenia (ITP) in adults, especially in patients with poor response to previous treatment, under the trade name Tavliesse. Subsequently, the drug also received corresponding medical use approval in the EU in January 2020 and was sold under the name Tavlesse.

The marketing of fotantinib is mainly based on two double-blind placebo-controlled clinical trials, namelyFIT-1 (NCT02076399) and FIT-2 (NCT02076412). These two studies involved a total of 150 adult patients. These patients were chronic ITP patients who had insufficient response to previous treatments (including corticosteroids, immunoglobulins, splenectomy, and thrombopoietin receptor agonists, etc.). The key indicator for efficacy evaluation is a stable platelet response, defined as a platelet count above 50*10^9/L on at least 4 out of 6 visits between weeks 14 and 24.

In theFIT-1 trial, 18% (n=9) of patients treated with fotantinib demonstrated a stable platelet response, compared with no patients in the placebo group (0%, n=0, p=0.03). Results from the FIT-2 trial showed that 16% (n=8) of patients in the fotantinib group and only 4% (n=1) of patients in the placebo group had a stable platelet response, although this difference did not reach statistical significance (p=0.26). In the subsequent FIT-3 (NCT 02077192) extension study, stable responses were also observed in 23% (n=10) of patients newly receiving fotantinib. These findings demonstrate that fotantinib is effective in providing durable platelet responses, bringing new hope to patients who have failed to respond to other treatments.

Although fotantinib has shown certain efficacy in ITP patients, attention should be paid to possible serious side effects during use. With reasonable precautions and dosage adjustments, these side effects can usually be effectively controlled. Therefore, its potential benefits and risks should be comprehensively considered during clinical application.

Reference materials:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fostamatinib-tablets-itp